Kyntra Bio (KYNB) Total Non-Current Liabilities (2014 - 2026)

Kyntra Bio has reported Total Non-Current Liabilities for 13 years, with the latest figure at $118.8 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 64.98% year-over-year to $118.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.8 million (down 64.98% YoY) and the FY2025 annual result came in at $115.0 million, down 71.05% from the prior year.
• Total Non-Current Liabilities grew to $118.8 million in Q1 2026 per KYNB's latest filing, from $115.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $605.1 million in Q4 2022 and troughed at $115.0 million in Q4 2025.
• A 5-year average of $439.5 million and a median of $543.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 37.26% in 2022, then sank 74.33% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $605.1 million in 2022, then slipped by 3.68% to $582.9 million in 2023, then sank by 31.83% to $397.3 million in 2024, then sank by 71.05% to $115.0 million in 2025, then grew by 3.31% to $118.8 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $118.8 million, $115.0 million, and $119.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.